Results 51 to 60 of about 11,782,455 (235)
AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury
Hepatology, EarlyView.
Robert J. Fontana +6 more
wiley +1 more source
Pathohistological characteristics of steatohepatitis on needle biopsy sample from 100 patients [PDF]
Introduction: Steatohepatitis is a form of fatty liver disease, in which there is a deposit of fat and steatosis which occurs in two forms: alcoholic and non-alcoholic fatty liver disease.
Milićević Anđela +2 more
doaj
Letter to the Editor: LO2, a misidentified cell line: Some data should be interpreted with caution
Hepatology, EarlyView.
Ralf Weiskirchen
wiley +1 more source
Background Non‐alcoholic fatty liver (NAFL) can progress to the severe subtype non‐alcoholic steatohepatitis (NASH) and/or fibrosis, which are associated with increased morbidity, mortality, and healthcare costs.
Sina Ghandian +7 more
doaj +1 more source
Rapid development of non-alcoholic steatohepatitis in Psammomys obesus (Israeli sand rat). [PDF]
BACKGROUND AND AIMS: A major impediment to establishing new treatments for non-alcoholic steatohepatitis is the lack of suitable animal models that accurately mimic the biochemical and metabolic characteristics of the disease.
Briana Spolding +16 more
doaj +1 more source
Non-alcoholic fatty liver disease is one of the main causes of elevated liver enzymes and chronic liver disease worldwide. It ranges from steatosis to steatohepatitis, leading to cirrhosis and related liver dysfunction.
Yeong Yeh Lee, Vincent Tee
doaj +1 more source
Glucagon‐Like Peptide‐1 Receptor Agonists in Multiple Sclerosis: A Topical Narrative Review
ABSTRACT The glucagon‐like peptide‐1 (GLP‐1) receptor agonists (RAs) are a relatively new class of drugs that were initially approved by the US Food and Drug Administration to improve glycemic control in patients with type 2 diabetes mellitus and, subsequently, weight reduction in patients with obesity.
Audrey Y. Chang, Farrah J. Mateen
wiley +1 more source
The aim of this work is to investigate the direct markers of liver fibrosis (LF) in patients with steatohepatitis non-alcoholic and alcoholic origin in combination with obesity (OB) and pathology of the biliary tract (BT). Materials and Methods.
A. Yu. Filippova
doaj +1 more source
Drug Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Fibrosis
Aim. An overview of current pharmacotherapy for non-alcoholic steatohepatitis (NASH)-associated liver fibrosis.Key points. In current clinical recommendations, therapeutic measures in non-alcoholic fatty liver disease should include lifestyle change ...
D. V. Garbuzenko
doaj +1 more source
Rab1A Promotes Hepatic Steatosis by Suppressing Mitophagy via the Raf‐1/ERK1/2/PINK1 Signaling Axis
Why does fat accumulate in the liver? Our study reveals Rab1A as the molecular switch that silences the cell's mitochondrial cleanup crew. Turning Rab1A off reactivates mitophagy, clears excess fat, and reverses fatty liver disease in mice—offering a promising new therapeutic target for MASLD, a growing global health challenge.
Li Zhang +9 more
wiley +1 more source

